ABBV Today - Aug 08: Stock May Be Undervalued

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

ABBV Today - Aug 08: Stock May Be Undervalued

無料で聴く

ポッドキャストの詳細を見る

Hey there! It’s Joey, your friendly investor buddy, here to break down the day for AbbVie. So, ABBV had a pretty chill day, barely moving, up just a bit—like 0.89%.

What went down? Well, it kinda stayed flat, just hovering around that $246 mark. Nothing too wild, right? But here's the scoop. There’s chatter that AbbVie might be 45% below its fair value because of its Rinvoq expansion in Europe. Sounds promising, but it didn’t really light a fire under the stock today.

Now, the reason for the slight dip earlier this week was a bit of a head-scratcher. They raised their 2026 revenue outlook, which usually gets people excited, but then they also announced some new debt. Talk about mixed signals, right? Investors hit the sell button a bit after that news dropped, and that stung.

Oh, and there’s some buzz about AbbVie in comparison to Abbott Laboratories. They’re being compared on who’s the better healthcare stock right now. It’s a bit of a showdown! And let’s not forget, there was a recent purchase of over 5,200 shares by MRA Advisory Group. Always interesting to see who’s buying in.

Looking ahead, keep an eye on Rinvoq’s rollout in Europe. That could be a game changer if it picks up traction.

So, that’s the lowdown on AbbVie today! Just remember, I’m here to keep you in the loop, not to give you any financial advice. Stay savvy out there! Catch you later!

まだレビューはありません